Abstract Kirsten Rat Sarcoma (KRAS) is a master oncogene involved in cellular proliferation
and survival and is the most commonly mutated oncogene in all cancers. Activating KRAS …

SOS1 and SOS2 are the most universal and widely expressed family of guanine exchange
factors (GEFs) capable or activating RAS or RAC1 proteins in metazoan cells. SOS proteins …

The 3 human RAS genes, KRAS, NRAS, and HRAS, encode 4 different RAS proteins which
belong to the protein family of small GTPases that function as binary molecular switches …

Activating mutations in the three human RAS genes, KRAS, NRAS and HRAS, are among
the most common oncogenic drivers in human cancers. Covalent KRASG12C inhibitors …

The impact of genetic ablation of SOS1 or SOS2 is evaluated in a murine model of
KRASG12D-driven lung adenocarcinoma (LUAD). SOS2 ablation shows some protection …

The study aimed to investigate the potential role of lysine-specific demethylase 5A (KDM5A)
in cisplatin-induced ototoxicity. The effect of the KDM5A inhibitor CPI-455 was assessed by …

Owing to several mutations, the oncogene Kirsten rat sarcoma 2 viral oncogene homolog
(KRAS) is activated in the majority of cancers, and targeting it has been pharmacologically …

The SOS family of Ras-GEFs encompasses two highly homologous and widely expressed
members, SOS1 and SOS2. Despite their similar structures and expression patterns, early …

About a third of tumors have activating mutations in HRAS, NRAS, or KRAS, genes encoding
guanosine triphosphatases (GTPases) of the RAS family. In these tumors, wild-type RAS …

KRAS is mutated in approximately 25% of cancer patients and first KRAS G12C-specific
inhibitors showed promising responses. Pancreatic cancer has the highest frequency of …